Stock Comparison

JNJ vs NVO

Johnson & Johnson vs Novo Nordisk A/S

The Verdict

NVO takes this one.

JNJ

Johnson & Johnson

1.0

out of 10

Distressed

Winner

NVO

Novo Nordisk A/S

1.4

out of 10

Distressed

Head-to-Head

N/A

Market Cap

$1.1T

N/A

P/E Ratio

10.7

N/A

Profit Margin

33.1%

N/A

Return on Equity

61.1%

N/A

Debt-to-Equity

0.7

Conservative

Overall Risk

Moderate

1.0

DVR Score

1.4

The Deep Dive

JNJ1.0/10

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Full JNJ Analysis

NVO1.4/10

Novo Nordisk (NVO) remains a formidable pharmaceutical giant, leading in diabetes and obesity care with its dominant GLP-1 franchise. The company is financially robust, boasts significant proprietary assets, and has a strategic vision for new therapeutic applications and AI integration. Recent FDA approvals for Wegovy HD and oral Wegovy are positive developments, enhancing its product portfolio. H...

Full NVO Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.